Bruce Cree, MD, PhD, MAS, FAAN

The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

At the 2023 ACTRIMS Forum, the clinical research director of the UCSF Multiple Sclerosis Center talked about the implications for patients on B-cell depleting therapies infected with COVID-19. [WATCH TIME: 4 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center spoke on the findings from two post-hoc analyses that were presented at the 2023 ACTRIMS Conference. [WATCH TIME: 3 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center provided perspective on the importance of serum neurofilament light and how it can be used in the management of patients with NMOSD. [WATCH TIME: 3 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center discussed the need for measures of progression in neuromyelitis optica and the next steps in treatment. [WATCH TIME: 4 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center provided insight on an abstract from ECTRIMS 2022 regarding inebilizumab’s mechanism of action to prevent NMOSD attacks. [WATCH TIME: 3 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center discussed the recently presented analysis on ublituximab’s effect on disability in relapsing MS and the critical need to focus on improving quality of life. [WATCH TIME: 4 minutes]

Bruce Cree, MD, PhD, MAS, FAAN, shared his thoughts on the data from the ULTIMATE I and II studies of ublituximab's effect on measures of MS disability, including EDSS and 9HPT scores.

The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center discussed new data presented at AAN on inebilizumab (Uplizna; Horizon) in neuromyelitis optica spectrum disorder. [WATCH TIME: 4 minutes]

Following the approval of 3 treatments for the disease, the clinical research director of the UCSF Multiple Sclerosis Center commented on the implications for the clinical development pipeline. [WATCH TIME: 4 minutes]

The clinical research director of the USCF Multiple Sclerosis Center discussed the importance of improving knowledge and education for patients with NMOSD, as well as strategies to do so. [WATCH TIME: 3 minutes]

Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]

The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]

Joseph R. Berger, MD, and Fred D. Lublin, MD, offer advice to community physicians and neurologists in managing patients with multiple sclerosis.

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

Kristen Krysko, MD, and Robert Fox, MD, look to the future of multiple sclerosis management. 

Considerations regarding the role of exercise and combatting fatigue when treating patients with multiple sclerosis.

The importance of proper nutrition as a therapy for symptom control in multiple sclerosis and some strategies to manage cognitive impairment. 

Joseph R. Berger, MD, elaborates on the importance of shared decision making in the treatment of multiple sclerosis and how it relates to complementary and natural therapies for symptom control.

The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.

Considerations regarding age in treatment decisions in patients with nonactive multiple sclerosis progression.

Experts discuss how they monitor response to multiple sclerosis therapies and disease progression.

Experts in progressive multiple sclerosis summarize the phase 2 SPRINT-MS trial and the rationale for treating patients with ibudilast.

A discussion of how experts treat nonactive multiple sclerosis in terms of trial results or symptom management and how decisions are based on patient age.

Experts in the field of multiple sclerosis discuss patient selection for drugs based on disease activity.

Kristen Krysko, MD, summarizes the results of the phase III ORATORIO trial and discusses the rationale for using ocrelizumab for the treatment of progressive multiple sclerosis.  

Experts in the field of multiple sclerosis compare the results of the EXPAND study to the results of the ASCEND study.

Robert Fox, MD, discusses the rationale for using siponimod for the treatment of progressive multiple sclerosis as well as the practical implications of the phase 3 EXPAND trial.

A comparison of various factors considered when treating primary progressive multiple sclerosis versus secondary progressive multiple sclerosis.